This is a working overview of pentadecapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-29. Anything still debated is marked as such rather than presented as settled.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
=== Pain === Preclinical data support the notion that Substance P is an important element in pain perception. The sensory function of Substance P is thought to be related to the transmission of pain information into the central nervous system. Substance P coexists with the excitatory neurotransmitter glutamate in primary afferents that respond to painful stimulation. Substance P and other sensory neuropeptides can be released from the peripheral terminals of sensory nerve fibers in the skin, muscle, and joints. It is proposed that this release is involved in neurogenic inflammation, which is a local inflammatory response to certain types of infection or injury. Unfortunately, the reasons why NK1 receptor antagonists have failed as efficacious analgesics in well-conducted clinical proof of concept studies have not yet been persuasively elucidated.
=== Insecticides === Parasites/bioinsecticides and chemical insecticides synergistically reduce fitness. Saddler et al., 2015 finds even An. gambiae with knockdown resistance (kdr) are more susceptible to DDT if they are first infected with Plasmodium berghei and Farenhorst et al., 2009 the same for Metarhizium robertsii or Beauveria bassiana. This is probably due to an effect found by Félix et al., 2010 and Stevenson et al., 2011: An. gambiae alters various activities – especially CYP6M2 – in response to P. berghei invasion. CYP6M2 is known to somehow produce pyrethroid resistance, and pyrethroids and DDT share a mechanism of action.
=== Pyridine carboxylic acids === Pyridine-2-carboxylic acid, pyridine-3-carboxylic acid, and pyridine-4-carboxylic acid are well established. They are colorless solids. The 3-isomer, also known as [nicotinic acid, is related to vitamin B6. They are typically produced commercially by oxidation of the corresponding methylpyridines.
In a woman with much breast tissue, for whom submuscular emplacement is the recommended surgical therapy, the aesthetic results of a saline breast-prosthesis are a proportionate breast-size, a smooth contour to the breast hemisphere, and anatomic symmetry, like the therapeutic results achieved with a prosthetic breast filled with silicone-gel.
When exposed to low oxygen concentrations, haemoglobin S polymerises into long strands within red blood cells (RBCs). These strands distort the shape of the cell and, after a few seconds, cause it to adopt an abnormal, inflexible, sickle-like shape. This process reverses when oxygen concentration is raised, and the cells resume their normal biconcave disc shape. If sickling takes place in the venous system, after blood has passed through the capillaries, it does not affect the organs, and the RBCs can unsickle when they become oxygenated in the lungs. Repeated switching between sickle and normal shapes damages the membrane of the RBC so that it eventually becomes permanently sickled. Normal red blood cells are quite elastic and have a biconcave disc shape, which allows the cells to deform to pass through capillaries. In sickle cell disease, low oxygen tension promotes red blood cell sickling and repeated sickling episodes damage the cell membrane and decrease the cell's elasticity. These cells fail to return to normal shape when oxygen tension is restored. As a consequence, these rigid blood cells are unable to deform as they pass through narrow capillaries, leading to vessel occlusion and ischaemia. Sickled cells are detected as they pass through the spleen and are destroyed. In young children with sickle cell disease, the accumulation of sickled cells in the spleen can result in splenic sequestration crisis. In this, the spleen becomes engorged with blood, depriving the general circulation of blood cells and leading to severe anaemia.
Sources: en.wikipedia.org
Around 500,000 BP a group of early humans, frequently called Homo heidelbergensis, came to Europe from Africa and eventually evolved into Homo neanderthalensis (Neanderthals). In the Middle Paleolithic, Neanderthals were present in the region now occupied by Poland. Both Homo erectus and Homo neanderthalensis became extinct by the start of the Upper Paleolithic. Descended from Homo sapiens, the anatomically modern Homo sapiens sapiens emerged in eastern Africa c. 300,000 BP, left Africa around 50,000 BP, and expanded throughout the planet. Multiple hominid groups coexisted for some time in certain locations. Homo neanderthalensis were still found in parts of Eurasia c. 40,000 BP years, and engaged in an unknown degree of interbreeding with Homo sapiens sapiens. DNA studies also suggest an unknown degree of interbreeding between Homo sapiens sapiens and Homo sapiens denisova. Hominin fossils not belonging either to Homo neanderthalensis or to Homo sapiens species, found in the Altai Mountains and Indonesia, were radiocarbon dated to c. 30,000 – c. 40,000 BP and c. 17,000 BP respectively. For the duration of the Paleolithic, human populations remained low, especially outside the equatorial region. The entire population of Europe between 16,000 and 11,000 BP likely averaged some 30,000 individuals, and between 40,000 and 16,000 BP, it was even lower at 4,000–6,000 individuals. However, remains of thousands of butchered animals and tools made by Palaeolithic humans were found in Lapa do Picareiro, a cave in Portugal, dating back between 41,000 and 38,000 years ago.
==== Full-size DisplayPort connector ==== The standard DisplayPort connector (now referred to as a "full-size" connector to distinguish it from the mini connector) was the sole connector type introduced in DisplayPort 1.0. It is a 20-pin single-orientation connector with a friction lock and an optional mechanical latch. The standard DisplayPort receptacle has dimensions of 16.10 mm (width) × 4.76 mm (height) × 8.88 mm (depth). The standard DisplayPort connector pin allocation is as follows:
== Education == Chilkoti obtained his Bachelor of Technology degree in Chemical Engineering from the IIT Delhi in 1985. He pursued his graduate studies at the University of Washington, where he earned his Ph.D. in Chemical Engineering in 1991, and carried out post-doctoral studies in the Center for Bioengineering from 1991 to 1995, also at the University of Washington.
Studies have been inconsistent across cultures regarding how balding men rate on the attraction scale. While a 2001 South Korean study showed that most people rated balding men as less attractive, a 2002 survey of Welsh women found that they rated bald and gray-haired men quite desirable. One of the proposed social theories for male pattern hair loss is that men who embraced complete baldness by shaving their heads subsequently signaled dominance, high social status, and/or longevity. Biologists have hypothesized the larger sunlight-exposed area would allow more vitamin D to be synthesized, which might have been a "finely tuned mechanism to prevent prostate cancer" as the malignancy itself is also associated with higher levels of DHT.
=== EC 1.4.1 With NAD+ or NADP+ as acceptor === EC 1.4.1.1: alanine dehydrogenase EC 1.4.1.2: glutamate dehydrogenase EC 1.4.1.3: glutamate dehydrogenase (NAD(P)+) EC 1.4.1.4: glutamate dehydrogenase (NADP+) EC 1.4.1.5: L-amino-acid dehydrogenase EC 1.4.1.6: deleted, Now included with EC 1.21.4.1, D-proline reductase (dithiol) EC 1.4.1.7: serine 2-dehydrogenase EC 1.4.1.8: valine dehydrogenase (NADP+) EC 1.4.1.9: leucine dehydrogenase EC 1.4.1.10: glycine dehydrogenase EC 1.4.1.11: L-erythro-3,5-diaminohexanoate dehydrogenase EC 1.4.1.12: 2,4-diaminopentanoate dehydrogenase EC 1.4.1.13: glutamate synthase (NADPH) EC 1.4.1.14: glutamate synthase (NADH) EC 1.4.1.15: lysine dehydrogenase EC 1.4.1.16: diaminopimelate dehydrogenase EC 1.4.1.17: N-methylalanine dehydrogenase EC 1.4.1.18: lysine 6-dehydrogenase EC 1.4.1.19: tryptophan dehydrogenase EC 1.4.1.20: phenylalanine dehydrogenase EC 1.4.1.21: aspartate dehydrogenase EC 1.4.1.22: there is no overall consumption of NAD+ during the reaction. As a result, transfer of the enzyme from EC 4.3.1.12 was not necessary and EC 1.4.1.22 was withdrawn before being made official EC 1.4.1.23: valine dehydrogenase (NAD+) EC 1.4.1.24: 3-dehydroquinate synthase II EC 1.4.1.25: L-arginine dehydrogenase EC 1.4.1.26: 2,4-diaminopentanoate dehydrogenase (NAD+) EC 1.4.1.27: glycine cleavage system
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.